AstraZeneca (AZN) Lower, Loses Certain CRESTOR Patent Decision
Tweet
Share
E-mailGet Alerts AZN Hot Sheet
Join SI Premium – FREE
AstraZeneca plc (NYSE: AZN) is ticking lower following headlines that it lost a ruling over 2018 and 2022 CRESTOR patents. Shares are down 0.7 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
- Cytokinetics aficamten meets dual endpoints in non-obstructive HCM trial
- FDA: issues early alert on Abiomed heart pump controller purge cassette issue
Create E-mail Alert Related Categories
FDA, Insiders' Blog, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
